News NeoGenomics, Inc.

Equities

NEO

US64049M2098

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
14.91 ^USD	+0.74%		-4.61%	-7.85%

May. 02	North American Morning Briefing : Stock Futures -3-	DJ
Apr. 30	Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stock Futures -3-	May. 02	DJ
Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating	Apr. 30	MT
Neogenomics Seeks M&A	Apr. 30	CI
Transcript : NeoGenomics, Inc., Q1 2024 Earnings Call, Apr 30, 2024	Apr. 30
NeoGenomics: Q1 Earnings Snapshot	Apr. 30	AQ
Earnings Flash (NEO) NEOGENOMICS Reports Q1 Revenue $156.2M, vs. Street Est of $149.7M	Apr. 30	MT
NeoGenomics Reports First Quarter 2024 Results	Apr. 30	BU
NeoGenomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024	Apr. 30	CI
NeoGenomics Announces Senior Leadership Promotions	Apr. 18	BU
NeoGenomics, Inc. Announces Senior Leadership Promotions	Apr. 18	CI
NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics	Apr. 18	CI
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024	Apr. 09	BU
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting	Mar. 27	BU
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report	Mar. 20	BU
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference	Mar. 04	AQ
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference	Mar. 01	BU
Piper Sandler Adjusts Price Target on NeoGenomics to $20 From $18, Maintains Overweight Rating	Feb. 26	MT
Goldman Sachs Raises Price Target on NeoGenomics to $19 From $17, Maintains Buy Rating	Feb. 22	MT
Needham Raises NeoGenomics' Price Target to $24 From $21, Keeps Buy Rating	Feb. 21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NeoGenomics, Inc.

Equities

NEO

US64049M2098

Summary

Filters